Brian A. Van Tine

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial

Hussein A. Tawbi, Melissa Burgess, Vanessa Bolejack et al. · The Lancet Oncology · 2017 · 1.4K citations · Full text

Oncology, Pathology, Advanced Soft-tissue Sarcoma +5

Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines

Kyle Ellrott, Matthew H. Bailey, Gordon Saksena et al. · Cell Systems · 2018 · 895 citations · Full text

Engineering, Genetics, Genomics +17

Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

Qingsong Gao, Wen-Wei Liang, Steven M. Foltz et al. · Cell Reports · 2018 · 633 citations · Full text

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

William D. Tap, Robin L. Jones, Brian A. Van Tine et al. · The Lancet · 2016 · 582 citations

Surgical Oncology, Oncology, Soft-tissue Sarcoma +7

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

Franz X. Schaub, Varsha Dhankani, Ashton C. Berger et al. · Cell Systems · 2018 · 434 citations · Full text